0.89
+7.51%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioNexus Gene Lab
From its filings with the US Securities and Exchange Commission
BioNexus Gene Lab is based in Kuala Lumpur and is incorporated in Wyoming. Its shares trade on Nasdaq under the ticker BGLC. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $7.4m and a net loss of $3.0m. At that date it held total assets of $9.3m and shareholders' equity of $8.6m.
In November 2025, the Company entered into a Share Subscription and Shareholders’ Agreement with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) and related parties, and also entered into an exclusive Southeast Asia intellectual property license arrangement relating to the VitaGuard™ minimal residual disease platform. These transactions expanded the Company’s strategic focus in molecular diagnostics and oncology-related screening technologies.
The Company, through its wholly owned subsidiary Chemrex, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia.
In addition, through its wholly owned subsidiary MRNA Scientific, the Company conducts genomic screening and related laboratory services. MRNA Scientific’s services involve blood-based analysis intended to provide risk-related information with respect to certain disease categories. The Company continues to evaluate MRNA Scientific’s operations, commercial opportunities, and strategic direction.
Quoted from its 10-K, filed 14 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 11 Mar 2020
- Employees
- 5
- Website
- bionexusgenelab.com ↗
- Head office
- UNIT A-28-7, TOWER A, MENARA UOA BANGSAR, KUALA LUMPUR, 59000
- Incorporated in
- WY
- Classification
- Services-Medical Laboratories
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Min Fong YeatChairman of the Board, since 2022$15,417
- Mr. Lee Su-Leng TanPresident, Chief Executive Officer, Chief Operating Officer
- Ms. Set Fui ChongChief Financial Officer
- Mr. Chi Yuen LeongDirector, since 2024
- Ms. Meng Wong YeeDirector, since 2022$15,417
- Ms. Jook LowIndependent Director
- Mr. Teong Teoh BoonIndependent Non-Executive Director
- Mr. Ping Lin ChaiIndependent Non-Executive Director
- Ms. Hua Yew ChakIndependent Non-Executive Director
- Mr. Teng Fook FongIndependent Non-Executive Director
- Mr. Chee Keong YapIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioNexus Gene Lab Corp. employs 5 full-time employees in Kuala Lumpur, Malaysia.
- The company's non-invasive blood tests analyze RNA changes for over 11 diseases.
- Bionexus Gene Lab Sdn. Bhd. serves as a subsidiary for the company's operations.
Weaknesses
- The company has only 5 full-time employees, limiting operational capacity.
- BioNexus Gene Lab Corp. went public on 11 March 2020, indicating recent market entry.
- Kuala Lumpur headquarters may restrict access to global talent pools.
Opportunities
- Expanding RNA-based blood tests to cover more diseases beyond 11.
- Growing demand for non-invasive diagnostics in the Malaysian healthcare sector.
- Potential partnerships with healthcare providers in Southeast Asia.
Threats
- Competition from established diagnostic firms in the Health Care sector.
- Regulatory challenges in Malaysia for new medical technologies.
- Economic downturns affecting healthcare spending in MY country.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.